For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Alcon AGALC SW · Health Care · CHF Current priceCHF 63.68as of Nov 19, 2026 Summary
Analyst consensusStrong Buy 3Buy 17Hold 6Strong Sell 117 analysts 3-year price (CHF)Factor profileMulti-factor score 57 / 100 Market data
Business descriptionAlcon AG is the global leader in eye care, operating across 60 countries and serving patients in over 140 markets. The company operates a focused two-segment model spanning Surgical (implantables, consumables, and equipment) and Vision Care (contact lenses and ocular health). Competitive moat
Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: CHF 63.68 · Nov 19, 2026· CHF
CFRA Ratingbuy
TBI Multi Score57
Theme Exposure
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart
ALC.SW62.70CHF+3.0%
Daily closes · Yahoo Finance · TradingView does not carry this exchange
Business description
Alcon AG is the global leader in eye care, operating across 60 countries and serving patients in over 140 markets. The company operates a focused two-segment model spanning Surgical (implantables, consumables, and equipment) and Vision Care (contact lenses and ocular health).
Competitive moat
- Market Leadership: Undisputed global leader in ophthalmic care with structurally advantaged positions in both surgical and vision care.
- Integrated Platforms: The Unity VCS/CS platform consolidates cataract and vitreoretinal surgery onto a single integrated console, delivering a 16% operating room efficiency gain.
- Installed Base: High barriers to entry reinforced by proprietary platforms deeply embedded in surgeon workflows, with a 30,000-unit global installed base eligible for upgrade.
- Internal Manufacturing: Approximately 90% of products are manufactured internally across 16 ISO-certified facilities.
Recent developments
- April 2026: Launched the Clareon TruPlus monofocal+ IOL in the US, expanding the addressable monofocal market.
- 2025: Launch of Unity VCS/CS platform, a major catalyst for the 10-year replacement cycle.
- Ocular Health: Tryptyr (prescription dry eye therapy) is outperforming expectations with strong refill rates and expanding commercial coverage.
- M&A: Failed acquisition of STAAR Surgical removes financing burden but misses access to the fast-growing implantable collamer lens market.
Investment risks / red flags
- Tariff Headwinds: Estimated $125M-$175M gross tariff impact in 2026 (net impact $50M-$100M after mitigation).
- Competition: Johnson & Johnson’s PureSee IOL is projected to pressure Alcon’s US PC-IOL franchise, potentially driving a 4% decline in that sub-segment in 2026.
- Segment Softness: Continued softness in the implantables segment (only ~2% growth in Q4 2025).
- Valuation: Trades at a notable forward premium (22.4x forward P/E) relative to peers like Johnson & Johnson (19.1x).
Market Data
Source: mkts.io · Nov 19, 2026, 16:00 UTC
Key Metrics
P/E (TTM)58.44
P/E (Fwd)17.66
Dividend0.45%
Beta0.72
52W HighCHF 68.34
52W LowCHF 47.80
Analyst Consensus
3
17
6
Strong Buy3Buy17Hold6Strong Sell117 analysts
Consensus TargetCHF 74.51
+17.0% upside
Calendar Events
Next EarningsNov 10, 2026
Ex-DividendMay 5, 2026
Dividend DateMay 15, 2025
Financials
RevenueCHF 10.98B
Rev Growth4.70%
Earnings Growth12.50%
Gross Margin57.92%
Op Margin12.93%
Profit Margin6.06%
EBITDACHF 2.39B
ROA2.82%
ROE3.04%
Rev/ShareCHF 22.60
Total CashCHF 1.81B
Total DebtCHF 5.34B
D/E Ratio24.57
Free Cash FlowCHF 1.28B
Op Cash FlowCHF 2.35B
Current Ratio2.50
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 0.50 | CHF 2.83B |
| +1q | 0.93 | CHF 2.96B |
| 0y | 3.49 | CHF 11.05B |
| +1y | 4.38 | CHF 11.72B |
Earnings
Quarterly EPS
3Q2025
Est: 0.850.79Miss
1Q2026
Est: 0.820.85Beat
3Q2026
Est: 0.890.91Beat
Annual
2022
Rev CHF 8.72BEarn CHF 335.00M
2023
Rev CHF 9.46BEarn CHF 974.00M
2024
Rev CHF 9.91BEarn CHF 1.02B
2025
Rev CHF 10.40BEarn CHF 980.00M
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 12, 2026 | Barclays | main | Equal-Weight |
| Nov 12, 2026 | Baird | main | Outperform |
| Nov 12, 2026 | Stifel | main | Hold |
| Nov 11, 2026 | BTIG | reit | Buy |
| Nov 11, 2026 | Needham | reit | Buy |
| Nov 2, 2026 | Needham | reit | Buy |
